FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2180336504> ?p ?o ?g. }

• W2180336504 endingPage "2104" @default.
• W2180336504 startingPage "2095" @default.
• W2180336504 abstract "Abstract Introduction Flibanserin, is a postsynaptic agonist of serotonin receptor 1A and an antagonist of serotonin receptor 2A, has been shown to increase sexual desire and reduce distress in women with hypoactive sexual desire disorder (HSDD). Aim We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. Methods A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of flibanserin for the treatment of HSDD. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Main Outcome Measures Four publications involving a total of 3,414 patients were used in the analysis, including four randomized controlled trials that compared flibanserin with placebo. Results For the comparison of flibanserin with placebo, primary efficacy endpoints: satisfying sexual events (the standardized mean difference [SMD] = 0.59, 95% confidence interval [CI] = 0.37–0.80, P &lt; 0.00001); sexual desire score (the SMD = 1.91, 95% CI = 0.21 to 3.60, P = 0.03) and Female Sexual Function Index (FSFI) desire domain score (the SMD = 0.32, 95% CI = 0.19–0.46, P &lt; 0.00001) and key secondary efficacy endpoints: FSFI total score, Female Sexual Distress Scale-Revised (FSDS-R) total score, FSDS-R Item 13 score, Patient's Global Impression of Improvement score and Patient Benefit Evaluation indicated that flibanserin was more effective than the placebo. Safety assessments included the proportion of women who experienced an adverse event (odds ratio = 1.54, 95% CI = 1.34 to 1.76, P &lt; 0.00001), nervous system disorders and fatigue indicated that flibanserin was well tolerated. Conclusions This meta-analysis indicates that flibanserin to be an effective and safe treatment for HSDD in women." @default.
• W2180336504 created "2016-06-24" @default.
• W2180336504 creator A5028456123 @default.
• W2180336504 creator A5039923970 @default.
• W2180336504 creator A5055795347 @default.
• W2180336504 creator A5061642965 @default.
• W2180336504 date "2015-11-01" @default.
• W2180336504 modified "2023-09-28" @default.
• W2180336504 title "Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis" @default.
• W2180336504 cites W1539592790 @default.
• W2180336504 cites W1550585548 @default.
• W2180336504 cites W1565489879 @default.
• W2180336504 cites W1571449955 @default.
• W2180336504 cites W1649598210 @default.
• W2180336504 cites W1877655410 @default.
• W2180336504 cites W1900483520 @default.
• W2180336504 cites W1928081212 @default.
• W2180336504 cites W1939923577 @default.
• W2180336504 cites W1972717804 @default.
• W2180336504 cites W1981947103 @default.
• W2180336504 cites W1990846924 @default.
• W2180336504 cites W2009836890 @default.
• W2180336504 cites W2034456325 @default.
• W2180336504 cites W2037280033 @default.
• W2180336504 cites W2094446562 @default.
• W2180336504 cites W2107328434 @default.
• W2180336504 cites W2125435699 @default.
• W2180336504 cites W2135650147 @default.
• W2180336504 cites W2139840896 @default.
• W2180336504 cites W2148926771 @default.
• W2180336504 cites W2154765734 @default.
• W2180336504 cites W2156072584 @default.
• W2180336504 cites W2158899784 @default.
• W2180336504 cites W2159917742 @default.
• W2180336504 cites W2160795987 @default.
• W2180336504 cites W2336273414 @default.
• W2180336504 cites W4239140289 @default.
• W2180336504 doi "https://doi.org/10.1111/jsm.13037" @default.
• W2180336504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26745616" @default.
• W2180336504 hasPublicationYear "2015" @default.
• W2180336504 type Work @default.
• W2180336504 sameAs 2180336504 @default.
• W2180336504 citedByCount "41" @default.
• W2180336504 countsByYear W21803365042016 @default.
• W2180336504 countsByYear W21803365042017 @default.
• W2180336504 countsByYear W21803365042018 @default.
• W2180336504 countsByYear W21803365042019 @default.
• W2180336504 countsByYear W21803365042020 @default.
• W2180336504 countsByYear W21803365042022 @default.
• W2180336504 countsByYear W21803365042023 @default.
• W2180336504 crossrefType "journal-article" @default.
• W2180336504 hasAuthorship W2180336504A5028456123 @default.
• W2180336504 hasAuthorship W2180336504A5039923970 @default.
• W2180336504 hasAuthorship W2180336504A5055795347 @default.
• W2180336504 hasAuthorship W2180336504A5061642965 @default.
• W2180336504 hasConcept C107993555 @default.
• W2180336504 hasConcept C118552586 @default.
• W2180336504 hasConcept C126322002 @default.
• W2180336504 hasConcept C142724271 @default.
• W2180336504 hasConcept C144024400 @default.
• W2180336504 hasConcept C15744967 @default.
• W2180336504 hasConcept C168563851 @default.
• W2180336504 hasConcept C204787440 @default.
• W2180336504 hasConcept C27081682 @default.
• W2180336504 hasConcept C2775871022 @default.
• W2180336504 hasConcept C2776710140 @default.
• W2180336504 hasConcept C2777092991 @default.
• W2180336504 hasConcept C2777877281 @default.
• W2180336504 hasConcept C2778093883 @default.
• W2180336504 hasConcept C28804328 @default.
• W2180336504 hasConcept C29456083 @default.
• W2180336504 hasConcept C53813258 @default.
• W2180336504 hasConcept C70410870 @default.
• W2180336504 hasConcept C71924100 @default.
• W2180336504 hasConcept C95190672 @default.
• W2180336504 hasConceptScore W2180336504C107993555 @default.
• W2180336504 hasConceptScore W2180336504C118552586 @default.
• W2180336504 hasConceptScore W2180336504C126322002 @default.
• W2180336504 hasConceptScore W2180336504C142724271 @default.
• W2180336504 hasConceptScore W2180336504C144024400 @default.
• W2180336504 hasConceptScore W2180336504C15744967 @default.
• W2180336504 hasConceptScore W2180336504C168563851 @default.
• W2180336504 hasConceptScore W2180336504C204787440 @default.
• W2180336504 hasConceptScore W2180336504C27081682 @default.
• W2180336504 hasConceptScore W2180336504C2775871022 @default.
• W2180336504 hasConceptScore W2180336504C2776710140 @default.
• W2180336504 hasConceptScore W2180336504C2777092991 @default.
• W2180336504 hasConceptScore W2180336504C2777877281 @default.
• W2180336504 hasConceptScore W2180336504C2778093883 @default.
• W2180336504 hasConceptScore W2180336504C28804328 @default.
• W2180336504 hasConceptScore W2180336504C29456083 @default.
• W2180336504 hasConceptScore W2180336504C53813258 @default.
• W2180336504 hasConceptScore W2180336504C70410870 @default.
• W2180336504 hasConceptScore W2180336504C71924100 @default.
• W2180336504 hasConceptScore W2180336504C95190672 @default.
• W2180336504 hasIssue "11" @default.
• W2180336504 hasLocation W21803365041 @default.
• W2180336504 hasLocation W21803365042 @default.

• next